Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lintuzumab-Ac225 and Venetoclax in Refractory or Relapsed AML
NCT03867682Phase 2Unknown
- Sponsor
- Actinium Pharmaceuticals, Inc.
- Start
- Jan 2020
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lintuzumab satetraxetan ac-225 in acute myeloid leukemia (AML), sponsored by Actinium Pharmaceuticals, Inc.. Status: unknown.
02
Drugs
lintuzumab satetraxetan ac-225
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03867682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867682.